A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02156076 |
Recruitment Status :
Terminated
(Sponsor decision based on business reasons, unrelated to safety)
First Posted : June 5, 2014
Results First Posted : May 22, 2019
Last Update Posted : July 31, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Paroxysmal Atrial Fibrillation | Drug: BMS-919373 Drug: Placebo (Matching with BMS-919373) | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 158 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Other |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation |
Actual Study Start Date : | July 25, 2014 |
Actual Primary Completion Date : | June 1, 2016 |
Actual Study Completion Date : | June 1, 2016 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Arm A: Placebo (Matching with BMS-919373)
Placebo (Matching with BMS-919373) 0 mg tablets orally once daily for approximately 28 Days
|
Drug: Placebo (Matching with BMS-919373) |
Experimental: Arm B: BMS-919373
BMS-919373 3 mg tablets orally once daily for approximately 28 days
|
Drug: BMS-919373 |
Experimental: Arm C: BMS-919373
BMS-919373 5 mg tablets orally once daily for approximately 28 days
|
Drug: BMS-919373 |
Experimental: Arm D: BMS-919373
BMS-919373 12 mg tablets orally once daily for approximately 28 days
|
Drug: BMS-919373 |
- Percent Change From Baseline in Atrial Fibrillation Burden (AFB) as Assessed by SEEQ Mobile Cardiac Telemetry (MCT) System [ Time Frame: Day 8 to Day 29 ]AFB is defined as the percent of time spent in atrial fibrillation (AF). AFB will be assessed by use of long term non- invasive beat-to-beat monitoring with the SEEQ MCT system. This technology consists of a low-profile adhesive patch that has been approved for continuous use for up to 30 days. The patch is able to continuously record electrocardiographic signals and, in conjunction with a wirelessly connected portable cellular communications device, transmit these signals for real-time analysis, including atrial and ventricular arrhythmias and AFB.
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-related AEs and Death [ Time Frame: Up to Day 50 ]An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product, whether or not considered related to the investigational product. A SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect.
- Maximum Observed Concentarion (Cmax) of BMS-919373 [ Time Frame: Day 1 and Day 22: Predose 1, 2, and 4 hours postdose ]Cmax is defined as the maximum observed concentration of BMS-919373.
- Trough Observed Concentration (Cmin) of BMS-919373 [ Time Frame: Day 8 (predose), Day 22 (predose, 1, 2, and 4 hours postdose), and Day 29 (24 hours after last dose of Day 28) ]Ctrough is defined as the minimum estimated plasma concentration at steady state.
- Oral Clearance (CL/F) of BMS-919373 [ Time Frame: Day 8 (predose), Day 22 (predose, 1, 2, and 4 hours postdose), and Day 29 (24 hours after last dose of Day 28) ]Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
- Central Volume of Distribution (Vc/F) of BMS-919373 [ Time Frame: Day 8 (predose), Day 22 (predose, 1, 2, and 4 hours postdose), and Day 29 (24 hours after last dose of Day 28) ]Volume of distribution is defined as the theoretical volume in which the total amount of drug is uniformly distributed to produce the desired plasma concentration of a drug. Vc/F is a hypothetical volume into which a drug initially distributes upon administration.
- Absorption Rate Constant (Ka) of BMS-919373 [ Time Frame: Day 8 (predose), Day 22 (predose, 1, 2, and 4 hours postdose), and Day 29 (24 hours after last dose of Day 28) ]Ka is the absorption rate constant.
- Average Concentration (Cavg) of BMS-919373 at Steady State [ Time Frame: Day 8 (predose), Day 22 (predose, 1, 2, and 4 hours postdose), and Day 29 (24 hours after last dose of Day 28) ]Cavg is defines as the average concentration at steady state.
- Area Under the Concentration-time Curve (AUC) at Steady State of BMS-919373 [ Time Frame: Day 8 (predose), Day 22 (predose, 1, 2, and 4 hours postdose), and Day 29 (24 hours after last dose of Day 28) ]AUC is defined as the area under the concentration-time curve at steady state.
- Time to First Atrial Fibrillation Recurrence (TTFR) (Symptomatic or Asymptomatic) [ Time Frame: Day 8 to Day 29 ]The TTFR is defined as the time to the first MCT-recorded AF episode after the first loading dose on Day 1. MCT will provide both "System-triggered" and "Patient-triggered" results and report them separately. "System-triggered" results will include both symptomatic and asymptomatic findings, while "Patient-triggered" results will be the symptomatic ones triggered to report by patients. The analysis will be done both for "System-triggered" and for "Patient-triggered" results.
- Total Number of Atrial Fibrillation Episodes [ Time Frame: Day 8 to Day 29 ]The total number AF episodes were derived from AF episode histogram data over the monitoring period.
- Average Duration of Atrial Fibrillation Per Episode [ Time Frame: Day 8 to Day 29 ]The average duration of AF per episode was calculated from the total time a participant in AF and the total number of AF episodes over the monitoring period.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Signed informed consent
- Paroxysmal Atrial Fibrillation (pAF) with available documentation of AF and reporting symptoms within 6 months prior to screening
- Able to tolerate withdrawal of antiarrhythmic therapy (rhythm control)
- Echocardiographically measured left ventricular ejection fraction (LVEF) ≥40%,measured within 12 months of enrollment
- Echocardiographically measured left atrial (LA) diameter ≤ 5.0 cm, measured within 12 months of enrollment
Exclusion Criteria:
- Women of childbearing potential
- AFB < 3% or > 70%, during both screening periods independently
- Permanent or persistent Atrial Fibrillation
- Cardioversion within 3 months of study drug administration
- Stroke within 12 months of study drug administration
- TIA within 12 months of study drug administration
- Heart failure of NYHA class III or greater (symptoms of heart failure at rest or with minimal exertion)
- Heart failure of NYHA class II (symptoms of heart failure with routine levels of exertion)with ejection fraction <40% as measured by echocardiography at any time within 12 months of study enrollment (i.e. additional ejection fraction measurements ≥ 40% over this period will not counter this exclusion)
- Valvular heart disease (including any valvular insufficiency or stenosis greater than"mild")
- Ablation within 3 months of study enrollment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02156076

Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Responsible Party: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT02156076 |
Other Study ID Numbers: |
CV205-005 |
First Posted: | June 5, 2014 Key Record Dates |
Results First Posted: | May 22, 2019 |
Last Update Posted: | July 31, 2019 |
Last Verified: | July 2019 |
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |